NL-OMON42081撤回3 期
A phase 3 prospective, multicenter study to evaluate efficacy and safety of rVWF with or without ADVATE in elective surgical procedures in subjects with severe von Willebrand disease - rVWF in subjects with VWD undergoing surgery
适应症
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 入组人数
- 2
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Subjects who meet ALL of the following criteria are eligible for this study:
- •1. Diagnosis of severe VWD as listed and elective surgical procedure planned:
- •- VWD with a history of requiring substitution therapy with von Willebrand factor concentrate
- •to control bleeding.
- •- Type 1 (VWF:RCo < 20 IU/dL) or
- •- Type 2A (as verified by multimer pattern), Type 2B (as diagnosed by genotype), Type 2N
- •(Factor VIII coagulation activity [FVIII:C] <10% and historically documented genetics),
- •- Type 3 (von Willebrand factor antigen [VWF:Ag] * 3 IU/dL)
- •2. If type 3 VWD (VWF:Ag * 3 IU/dL), subject has a medical history of at least 20 EDs to VWF/FVIII
- •coagulation factor concentrates (including cryoprecipitate or fresh frozen plasma).
- •3. If type 1 or type 2 VWD, subject has a medical history of 5 EDs or a past major surgery requiring
- •VWF/FVIII coagulation factor concentrates (including cryoprecipitate or fresh frozen plasma).
- •4. At least 18 years of age
- •5. If female of childbearing potential, subject presents with a negative pregnancy test
- •6. If applicable, subject agrees to employ adequate birth control measures for the duration of the study
- •7. Willing and able to comply with the requirements of the protocol.
排除标准
- •Subjects who meet ANY of the following criteria are not eligible for this study:
- •1. Diagnosis of pseudo VWD or another hereditary or acquired coagulation disorder (eg qualitative and quantitative platelet disorders or elevated PT/ international normalized ratio [INR] * 1.4)
- •2. History or presence of a VWF inhibitor at screening
- •3. History or presence of a factor VIII (FVIII) inhibitor with a titer * 0.4 BU (by Nijmegen-modified
- •Bethesda assay ) or * 0.6 BU (by Bethesda assay)
- •4. Known hypersensitivity to any of the components of the study drugs, such as to mouse or hamster proteins
- •5. Medical history of immunological disorders, excluding seasonal allergic rhinitis/conjunctivitis, mild asthma, food allergies or animal allergies
- •6. Medical history of a thromboembolic event
- •7. HIV positive with an absolute CD4 count *200/mm3
- •8. Platelet count < 100,000/mL
- •9. Diagnosis of significant liver disease, as evidenced by, but not limited to, any of the following: serum alanine aminotransferase (ALT) 5 times the upper limit of normal; hypoalbuminemia; portal vein hypertension (e.g. presence of otherwise unexplained splenomegaly, history of esophageal varices) or liver cirrhosis classified as Child B or C
- •10. Diagnosis of renal disease, with a serum creatinine level *2.5 mg/dL
- •11. Subject has been treated with an immunomodulatory drug, excluding topical treatment (e.g.
- •ointments, nasal sprays), within 30 days prior to signing the informed consent
- •12. Subject is pregnant or lactating at the time informed content is obtained.
- •13. Subject has participated in another clinical study involving an investigational product (IP), other than rVWF with or without ADVATE , or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study. (Eligible patients participating in the rVWF Prophy study [071301] may be enrolled).
- •14. Progressive fatal disease and/or life expectancy of less than 3 months
- •15. Subject is identified by the investigator as being unable or unwilling to cooperate with study
- •16. Subject suffers from a mental condition rendering him/her unable to understand the nature, scope and possible consequences of the study and/or evidence of an uncooperative attitude
- •17. Subject is in prison or compulsory detention by regulatory and/or juridical order
- •18. Member of the study team conducting this study or in a dependent relationship with one of the study team members. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees.
研究者
相似试验
进行中（未招募）
1 期
umason™/SonoVue® in Stress Echocardiography with Dobutamine for the Diagnosis of Coronary Artery DiseaseSuspected or known Coronary Artery DiseaseMedDRA version: 18.1Level: HLGTClassification code 10011082Term: Coronary artery disordersSystem Organ Class: 10007541 - Cardiac disordersEUCTR2015-001962-25-BEBracco Imaging S.p.A.175
进行中（未招募）
1 期
umason™/SonoVue® in Stress Echocardiography with Dobutamine for the Diagnosis of Coronary Artery DiseaseSuspected or known Coronary Artery DiseaseMedDRA version: 20.0Level: HLGTClassification code 10011082Term: Coronary artery disordersSystem Organ Class: 10007541 - Cardiac disordersEUCTR2015-001713-28-DEBracco Imaging S.p.A.175
进行中（未招募）
1 期
umason™/SonoVue® in Stress Echocardiography with Dobutamine for the Diagnosis of Coronary Artery DiseaseSuspected or known Coronary Artery DiseaseMedDRA version: 18.0Level: HLGTClassification code 10011082Term: Coronary artery disordersSystem Organ Class: 10007541 - Cardiac disordersEUCTR2015-001962-25-GBBracco Imaging S.p.A.175
进行中（未招募）
不适用
Assessment of the efficacy of PGL4001 in repeated treatment courses on reducing symptoms of uterine fibroids causing heavy menstrual periodsterine myomas are benign, monoclonal, hormone-sensitive, smooth muscle tumours of the uterus. They are the most common tumour of the female reproductive tract in pre-menopausal women and mostly asymptomatic affecting approximately 40% of women between 35 and 55 years. When symptomatic, the main symptoms are heavy uterine bleeding, abdominal pressure, abdominal pain, increased urinary frequency and infertility.MedDRA version: 14.0Level: LLTClassification code 10046801Term: Uterine myomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019497-32-PLPregLem S.A.200
进行中（未招募）
不适用
PGL4001 Efficacy Assessment in Reduction of symptoms due to uterine Leiomyomataterine myomas are benign, monoclonal, hormone-sensitive, smooth muscle tumours of the uterus. They are the most common tumour of the female reproductive tract in pre-menopausal women and mostly asymptomatic affecting approximately 40% of women between 35 and 55 years. When symptomatic, the main symptoms are heavy uterine bleeding, abdominal pressure, abdominal pain, increased urinary frequency and infertility.MedDRA version: 14.0Level: LLTClassification code 10046801Term: Uterine myomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-018999-25-ATPregLem S.A.200